News

Contract Pharma8d
Overcoming Challenges in Early Phase Drug Product Development
Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...
Contract Pharma1d
Thermo Fisher Streamlines Pre-Clinical Biologic Drug Development
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...
Interesting Engineering on MSN1d
Reversible male birth control injectable lasts 2 years, moves to phase 2 human trials
Contraline, a biotech company, has received regulatory approval to move onto Phase 2 of human clinical trials for a male ...
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...
Clinical Trials Arena on MSN5d
Redefining the future of clinical trials in oncology
The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...
Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Advances Measles Drug Development With Broad-Spectrum Antiviral NV-387
NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectru ...
The Manila Times15h
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different ...
Morningstar6d
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody ... 1310 data at ASCO and outline the next steps in clinical development. Date/Time: Monday, June 2, 2025, at 7:00 a.m. CT ...